Becker's Healthcare September 21, 2022
Paige Twenter

Pharmaceutical companies have years to find loopholes in the Inflation Reduction Act — a law recently signed that aims to lower drug costs — and legal experts say the delayed implementation could hinder its goals, NBC News reported Sept. 20.

The legislation, totalling $739 billion, was signed into law Aug. 16. Its terms include capping Medicare’s insulin prices at $35 per month starting in 2023, limiting out-of-pocket Medicare costs to $2,000 per month in 2025 and allowing the FDA to negotiate prices for 10 drugs in 2026.

Because it will take four years for the IRA to be fully implemented, some health policy experts are concerned about the various strategies drugmakers can use to bypass the law.

“Trying...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech, Regulations
Brazil’s plan for low-cost CAR-Ts
PacBio’s Repeat Expansion Panel, Owkin-Sanofi AI Take on Immunology, More
STAT+: Borrowing an idea from cancer immunotherapy, scientists make old-mice immune systems youthful again
Moderna gets Blackstone backing for flu vaccine R&D
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension

Share This Article